Cardiac Manifestations of Noncardiac Disease in the Elderly

  • David W. Snyder
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 76)


In the elderly population, the heart may be involved secondarily by disease elsewhere in the body or be affected by a systemic disorder. Thus renal disease, lung disease, and hypertension may place excessive demands on the heart, which can lead to cardiac decompensation. Direct involvement in a systemic process may be seen in some endocrine abnormalities, collagen-vascular diseases, or infiltrative processes such as amyloidosis. In this chapter we will review some of the more common extracardiac diseases that lead to cardiac dysfunction in the aged.


Chronic Obstructive Pulmonary Disease Atrial Fibrillation Pulmonary Hypertension Chronic Obstructive Pulmonary Disease Patient Pulmonary Vascular Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ferrer MI. Management of patients with cor pulmonale. Med Clin North Am 63:251–265, 1979.PubMedGoogle Scholar
  2. 2.
    Enson Y, Giuntini C, Lewis ML, et al. The influence of hydrogen ion concentration and hypoxia on the pulmonary circulation. J Clin Invest 43:1146–1162, 1964.PubMedCrossRefGoogle Scholar
  3. 3.
    Tirlapur VG and Mir MA. Nocturnal hyopoxemia and associated electrocardiographic changes in patients with chronic obstructive airways disease. N Engl J Med 306:125–130, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Anthonisen NR. Long-term oxygen therapy. Ann Intern Med 99:519–527, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    Matthay RA, Berger HJ, Loke J, et al. Effects of aminophylline on right and left ventricular performance in chronic obstructive pulmonary disease. Am J Med 65:903–910, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Winter RJD, Langford JA, and Rudd RM. Effects of oral and inhaled salbutamol and oral pirbuterol on right and left ventricular function in chronic bronchitis. Brit Med J 288:324–325, 1984.Google Scholar
  7. 7.
    Parker JO, Ashekian PB, DiGiorgi S, et af. Hemodynamic effects of aminophylline in chronic obstructive pulmonary disease. Circulation 36:365–372, 1967.CrossRefGoogle Scholar
  8. 8.
    Matthay RA, Berger HJ, Davies R, et al. Improvement in cardiac performance by oral long-acting theophylline in chronic obstructive pulmonary disease. Am Heart J 104:1022–1029, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Green LH and Smith TW. The use of digitalis in patients with pulmonary disease. Ann Intern Med 87:459–465, 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    Mathur PN, Powles P, Pugsley SO, et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. Ann Intern Med 95:283–288, 1981.PubMedCrossRefGoogle Scholar
  11. 11.
    Brown SE, Pakron FJ, Milne N, et al. Effects of digoxin on exercise capacity and right ventricular function during exercise in chronic airflow obstruction. Chest 85:187–191, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    Weisse AB, Moschos CB, Frank MJ, et al. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med 58:92–98, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Sturani C, Bassein L, Schiavina M, et al. Oral nifedipine in chronic cor pulmonale secondary to severe chronic obstructive pulmonary disease (COPD). Chest 84:135–142, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Kennedy TP, Michael JR, and Summer W. Calcium channel blockers in hypoxic pulmonary hypertension. Am J Med 78 (suppl 2B): 18–26, 1985.PubMedCrossRefGoogle Scholar
  15. 15.
    Holford FD and Mithoefer JC. Cardiac arrhythmias in hospitalized patients with chronic obstructive pulmonary disease. Am Rev Resp Dis 108:879–885, 1973.PubMedGoogle Scholar
  16. 16.
    Kleiger RE and Senior RM. Long-term electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest 65:483–488, 1974.PubMedCrossRefGoogle Scholar
  17. 17.
    Hudson LD, Kurt TL, Petty TL, et al. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest 63:661–665, 1973.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldberg LM, Bristow JD, Parker BM, et al. Paroxysmal atrial tachycardia with atrioventricular block. Circulation 21:499–504, 1960.CrossRefGoogle Scholar
  19. 19.
    Nordstrom LA, MacDonald F, and Gobel F. Effect of propranolol on respiratory function and exercise tolerance in patients with chronic obstructive lung disease. Chest 67:287–292, 1975.PubMedCrossRefGoogle Scholar
  20. 20.
    Esmolol Multicenter Research Group. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: A multicenter double-blind clinical trial. Am Heart J 110:913–920, 1985.CrossRefGoogle Scholar
  21. 21.
    Zipes DP, Prystowsky EN, and Heger JJ. Amiodarone: Electrophysiologic actions, pharmacokinetics, and clinical effects. J Am Coll Cardiol 3:1059–1071, 1984.PubMedCrossRefGoogle Scholar
  22. 22.
    Horowitz LN and Morganroth J. Second generation anti-arrhythmic agents: Have we reached antiarrhythmic Nirvana? J Am Coll Cardiol 9: 459–463, 1987.PubMedCrossRefGoogle Scholar
  23. 23.
    Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697–701, 1974.PubMedCrossRefGoogle Scholar
  24. 24.
    Capelli JP and Kasparian H. Cardiac work demands and left ventricular function in end-stage renal disease. Ann Intern Med 86:261–265, 1977.PubMedCrossRefGoogle Scholar
  25. 25.
    Neff MS, Kim KE, Persoff M, et al. Hemodynamics of uremic anemia. Circulation 43:876–883, 1971.PubMedCrossRefGoogle Scholar
  26. 26.
    Menno AD, Zizzi J, Hodson J, et al. An evaluation of the radial arteriovenous fistula as a substitute for the Quinton shunt in chronic hemodialysis. Trans Am Soc Artif Intern Organs 8:62–67, 1967.Google Scholar
  27. 27.
    Huug J, Harris PJ, Uren RF, et al. Uremic cardiomyopathy—Effect of hemodialysis on left ventricular function in end-stage renal failure. N Engl J Med 302:547–551, 1980.CrossRefGoogle Scholar
  28. 28.
    Comty CM, Cohen SL, and Shapiro FL. Pericarditis in chronic uremia and its sequela. Ann Intern Med 75:173–183, 1971.PubMedCrossRefGoogle Scholar
  29. 29.
    Jelliffe RW. Factors to consider in planning digoxin therapy. J Chronic Dis 24:407–416, 1971.PubMedCrossRefGoogle Scholar
  30. 30.
    Silverberg S, Oreopoulos DG, Wise DJ, et al. Pericarditis in patients undergoing long-term hemodialysis and peritoneal dialysis. Am J Med 63:874–880, 1977.PubMedCrossRefGoogle Scholar
  31. 31.
    Tibaldi JM, Barzel US, Albin J, and Surks M. Thyrotoxicosis in the very old. Am J Med 81:619–622, 1986.PubMedCrossRefGoogle Scholar
  32. 32.
    Symons C. Thyroid heart disease. Br Heart J 41:257–262, 1979.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakazawa AK, Sakurai K, Hamada N, et al. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 72:903–906, 1982.PubMedCrossRefGoogle Scholar
  34. 34.
    Staffurth JS, Gibberd MC, and Ng Tang Fui S. Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 2:688–690, 1977.PubMedCrossRefGoogle Scholar
  35. 35.
    Buccino RA, Spann JF Jr, Pool PE, et al. Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest 46:1669–1682, 1967.PubMedCrossRefGoogle Scholar
  36. 36.
    Crowley WF, Jr, Ridgway EC, Bough EW, et al. Noninvasive evaluation of cardiac function in hyperthyroidism. N Engl J Med 296:1–6, 1977.PubMedCrossRefGoogle Scholar
  37. 37.
    Santos AD, Miller RP, Mathew PK, et al. Echocardigraphic characterization of the reversible cardiomyopathy of hypothyroidism. Am J Med 68:675–682, 1980.PubMedCrossRefGoogle Scholar
  38. 38.
    Steinberg AD. Myxedema and coronary artery disease—A comparative autopsy study. Ann Intern Med 68:338–344, 1968.PubMedCrossRefGoogle Scholar
  39. 39.
    Bastenie PA, Bonnyns M, and Vanhaelst L. Natural history of primary myxedema. Am J Med 79:91–100, 1985.PubMedCrossRefGoogle Scholar
  40. 40.
    Rosenbaum RL and Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med 96:53–55, 1982.PubMedCrossRefGoogle Scholar
  41. 41.
    Keating FR, Parkin TW, Selby JB, et al. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 3: 364–386, 1960.Google Scholar
  42. 42.
    Hay ID, Duick DS, Vlietstra RE, et al. Thyroxine therapy in hypothyroid patients undergoing coronary revascularization: A retrospective analysis. Ann Intern Med 95:456–457, 1981.PubMedCrossRefGoogle Scholar
  43. 43.
    Goodman BW. Temporal arteritis. Am J Med 67:839–852, 1979.PubMedCrossRefGoogle Scholar
  44. 44.
    Klein RG, Hunder GG, Stanson AW, et al. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 83:806–812, 1975.PubMedCrossRefGoogle Scholar
  45. 45.
    Bacon PA and Gibson DG. Cardiac involvement in rheumatoid arthritis. An echocardiographic study. Ann Rheum Dis 33:20–24, 1974.PubMedCrossRefGoogle Scholar
  46. 46.
    Kirk J and Cosh J. The pericarditis of rheumatoid arthritis. Quart J Med 38:397–423, 1969.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1987

Authors and Affiliations

  • David W. Snyder

There are no affiliations available

Personalised recommendations